X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GSK PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GSK PHARMA CADILA HEALTHCARE/
GSK PHARMA
 
P/E (TTM) x 32.1 63.0 51.0% View Chart
P/BV x 6.0 10.1 59.0% View Chart
Dividend Yield % 0.8 1.3 63.0%  

Financials

 CADILA HEALTHCARE   GSK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
GSK PHARMA
Mar-17
CADILA HEALTHCARE/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs4603,838 12.0%   
Low Rs3052,637 11.6%   
Sales per share (Unadj.) Rs92.1354.2 26.0%  
Earnings per share (Unadj.) Rs14.839.8 37.3%  
Cash flow per share (Unadj.) Rs18.542.9 43.1%  
Dividends per share (Unadj.) Rs3.2030.00 10.7%  
Dividend yield (eoy) %0.80.9 90.3%  
Book value per share (Unadj.) Rs68.0236.9 28.7%  
Shares outstanding (eoy) m1,023.7484.70 1,208.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.29.1 45.4%   
Avg P/E ratio x25.881.4 31.7%  
P/CF ratio (eoy) x20.775.5 27.4%  
Price / Book Value ratio x5.613.7 41.2%  
Dividend payout %21.675.4 28.6%   
Avg Mkt Cap Rs m391,581274,216 142.8%   
No. of employees `00016.94.7 358.8%   
Total wages/salary Rs m15,0024,830 310.6%   
Avg. sales/employee Rs Th5,594.56,387.0 87.6%   
Avg. wages/employee Rs Th890.11,028.3 86.6%   
Avg. net profit/employee Rs Th899.9717.1 125.5%   
INCOME DATA
Net Sales Rs m94,29530,000 314.3%  
Other income Rs m1,286728 176.6%   
Total revenues Rs m95,58130,728 311.1%   
Gross profit Rs m19,0364,190 454.3%  
Depreciation Rs m3,750263 1,425.9%   
Interest Rs m4500-   
Profit before tax Rs m16,1224,655 346.3%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3457 -0.7%   
Tax Rs m1,2891,744 73.9%   
Profit after tax Rs m15,1683,368 450.4%  
Gross profit margin %20.214.0 144.5%  
Effective tax rate %8.037.5 21.3%   
Net profit margin %16.111.2 143.3%  
BALANCE SHEET DATA
Current assets Rs m60,22316,742 359.7%   
Current liabilities Rs m53,0587,202 736.7%   
Net working cap to sales %7.631.8 23.9%  
Current ratio x1.12.3 48.8%  
Inventory Days Days7052 134.8%  
Debtors Days Days8821 424.2%  
Net fixed assets Rs m72,9848,635 845.2%   
Share capital Rs m1,024847 120.9%   
"Free" reserves Rs m68,57619,222 356.8%   
Net worth Rs m69,60020,069 346.8%   
Long term debt Rs m24,68410 246,840.0%   
Total assets Rs m152,20730,038 506.7%  
Interest coverage x36.8NM-  
Debt to equity ratio x0.40 71,174.2%  
Sales to assets ratio x0.61.0 62.0%   
Return on assets %10.311.2 91.5%  
Return on equity %21.816.8 129.9%  
Return on capital %17.925.5 70.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,280528 4,030.3%   
Fx outflow Rs m10,8747,193 151.2%   
Net fx Rs m10,406-6,665 -156.1%   
CASH FLOW
From Operations Rs m13,4952,360 571.8%  
From Investments Rs m-29,1033,008 -967.5%  
From Financial Activity Rs m23,158-5,108 -453.4%  
Net Cashflow Rs m7,556260 2,902.8%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 8.3 10.2 81.4%  
FIIs % 5.9 23.8 24.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 15.4 71.4%  
Shareholders   44,069 102,036 43.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 23, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS